| 1 |
Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies[J]. BMJ, 2008, 336(7653): 1106-1110.
|
| 2 |
Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009) [DB/OL]. Oxford Centre for Evidence-based Medicine, 2009[2018-11-01].
URL
|
| 3 |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
|
| 4 |
Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17(Suppl 2): S44-S57.
|
| 5 |
European Liver Transplant Registry Results[DB/OL]. European Liver Transplant Registry, 2011[2018-11-01].
URL
|
| 6 |
OPTN/SRTR Annual Report[DB/OL]. Organ Procurement and Transplantation Network, 2011[2018-11-01].
URL
|
| 7 |
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6):1394-1403.
|
| 8 |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1): 35-43.
|
| 9 |
Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences[J]. Transplantation, 2008, 85(12): 1726-1732.
|
| 10 |
Audet M, Panaro F, Piardi T, et al. Are the Hangzhou criteria adaptable to hepatocellular carcinoma patients for liver transplantation in Western countries？[J]. Liver Transpl, 2009, 15(7): 822-823.
|
| 11 |
Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma[J]. PLoS One, 2014, 9(3): e93128.
|
| 12 |
徐骁，杨家印，钟林，等. 肝癌肝移植"杭州标准"多中心应用研究——1163例报道[J]. 中华器官移植杂志，2013, 34(9):524-527.
|
| 13 |
Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience[J]. Eur J Gastroenterol Hepatol, 2014, 26(2): 200-204.
|
| 14 |
Xiao GQ, Yang JY, Yan LN. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(6): 588-595.
|
| 15 |
Fu H, Zheng J, Cai J, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within Hangzhou criteria[J]. Cell Physiol Biochem, 2018, 47(1):293-301.
|
| 16 |
Xu X, Lu D, Ling Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6):1035-1041.
|
| 17 |
Zhang X, Li C, Wen T, et al. Outcomes of salvage liver transplantation and re-resection/radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: A new surgical strategy based on recurrence pattern[J]. Dig Dis Sci, 2018, 63(2): 502-514.
|
| 18 |
Hu Z, Wang W, Li Z, et al. Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis[J]. Liver Transpl, 2012, 18(11): 1316-1323.
|
| 19 |
Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-e22.
|
| 20 |
Chapman WC, Garcia-Aroz S, Vachharajani N, et al. Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions[J]. J Am Coll Surg, 2017, 224(4): 610-621.
|
| 21 |
Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma[J]. Int J Hepatol, 2013: 419302.
|
| 22 |
European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
|
| 23 |
Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 151(6):1155-1163.
|
| 24 |
Klompenhouwer EG, Dresen RC, Verslype C, et al. Safety and efficacy of transarterial radioembolisation in patients with intermediate or advanced stage hepatocellular carcinoma refractory to chemoembolisation[J]. Cardiovasc Intervent Radiol, 2017, 40(12): 1882-1890.
|
| 25 |
Graziadei I, Zoller H, Fickert P, et al. Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (OGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)[J]. Wien Klin Wochenschr, 2016, 128(19-20): 679-690.
|
| 26 |
Samoylova ML, Dodge JL, Yao FY, et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation[J]. Liver Transpl, 2014, 20(8): 937-944.
|
| 27 |
Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation[J]. Liver Transpl, 2013, 19(10):1108-1118.
|
| 28 |
Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria[J]. Gastroenterology, 2012, 143(4): 986-994.
|
| 29 |
Ashoori N, Bamberg F, Paprottka P, et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation[J]. Digestion, 2012, 86(4): 338-348.
|
| 30 |
Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma[J]. J Hepatol, 2011, 55(4): 814-819.
|
| 31 |
Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum alpha-fetoprotein levels in liver transplant for hepatocellular cancer[J]. Arch Surg, 2011, 146(1): 26-33.
|
| 32 |
Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)？[J]. Liver Transpl, 2018, 24(3): 327-329.
|
| 33 |
Llovet JM, Pavel M, Rimola J, et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan criteria (Barcelona clinic liver cancer extended criteria)[J]. Liver Transpl, 2018, 24(3): 369-379.
|
| 34 |
European Association for the Study of the Liver. EASL clinical practice guidelines: Liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485.
|
| 35 |
Sastre J, Diaz-Beveridge R, Garcia-Foncillas J, et al. Clinical guideline SEOM: hepatocellular carcinoma[J]. Clin Transl Oncol, 2015, 17(12): 988-995.
|
| 36 |
Qu LS, Liu JX, Zhu J, et al. Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis B viral load[J]. Ann Hepatol, 2017, 16(3): 412-420.
|
| 37 |
Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 33(10): 1104-1112.
|
| 38 |
Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function[J]. Intern Med, 2009, 48(1): 11-17.
|
| 39 |
European Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
|
| 40 |
Hu TH, Chen CL, Lin CC, et al. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation[J]. Transplantation, 2014, 97(Suppl 8):S53-S59.
|
| 41 |
Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29): 3647-3655.
|
| 42 |
Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy[J]. Hepatology, 2013, 57(1): 399-408.
|
| 43 |
Huang G, Lai EC, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3): 490-505.
|
| 44 |
Chen CJ, Yang HI, Iloeje UH; Group R-HS. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B[J]. Hepatology, 2009, 49(5 Suppl): S72-S84.
|
| 45 |
Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years[J]. Hepatology, 2017, 66(4): 1036-1044.
|
| 46 |
Kim JM, Joh JW, Kim SJ, et al. Steroid withdrawal in adult liver transplantation: occurrence at a single center[J]. Transplant Proc, 2010, 42(10): 4132-4136.
|
| 47 |
Lo CM, Lau GK, Chan SC, et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B[J]. Am J Transplant, 2007, 7(2): 434-439.
|
| 48 |
Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B[J]. J Hepatol, 2005, 43(2): 283-287.
|
| 49 |
Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation[J]. Hepatology, 2000, 31(2): 496-501.
|
| 50 |
Younossi ZM, Stepanova M, Sulkowski M, et al. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study[J]. Liver Int, 2017, 37(12): 1796-804.
|
| 51 |
Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from astral-2 and -3 clinical trials[J]. Clin Infect Dis, 2016, 63(8): 1042-1048.
|
| 52 |
Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial[J]. J Hepatol, 2016, 65(1): 33-39.
|
| 53 |
Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(2): 122-132.
|
| 54 |
Levitsky J, Verna EC, O′Leary JG, et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients[J]. N Engl J Med, 2016, 375(21):2106-2108.
|
| 55 |
Terrault NA, McCaughan GW, Curry MP, et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates[J]. Transplantation, 2017, 101(5):945-955.
|
| 56 |
Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study[J]. Gastroenterology, 2015, 148(1): 100-107.
|
| 57 |
Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience[J]. J Gastroenterol, 2017, 52(8): 986-991.
|
| 58 |
Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients[J]. J Hepatol, 2017, 67(3): 585-602.
|
| 59 |
Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial[J]. Lancet Infect Dis, 2016, 16(6): 685-697.
|
| 60 |
Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation[J]. N Engl J Med, 2014, 371(25): 2375-2382.
|
| 61 |
Chen K, Man K, Metselaar HJ, et al. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation[J]. Liver Transpl, 2014, 20(3): 261-269.
|
| 62 |
Wei Q, Gao F, Zhuang R, et al. A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437.
|
| 63 |
Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634.
|
| 64 |
Geissler EK, Schnitzbauer AA, Zulke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1): 116-125.
|
| 65 |
Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(4): 411-419.
|
| 66 |
Foroncewicz B, Mucha K, Ryszkowska E, et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center[J]. Transplant Proc, 2009, 41(8): 3103-3106.
|
| 67 |
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5): 857-62.
|
| 68 |
Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients[J]. Liver Transpl, 2003, 9(2): 126-129.
|
| 69 |
Cholongitas E, Mamou C, Rodríguez-Castro KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10):1039-1049.
|
| 70 |
Xu SL, Zhang YC, Wang GY, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2016, 40(6): 674-681.
|
| 71 |
Tarantino G, Magistri P, Ballarin R, et al. Oncological impact of M-Tor inhibitor immunosuppressive therapy after liver transplantation for hepatocellular carcinoma: Review of the literature[J]. Front Pharmacol, 2016, 7: 387.
|
| 72 |
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
|
| 73 |
Bodzin AS, Lunsford KE, Markovic D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: Impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125.
|
| 74 |
Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294.
|
| 75 |
Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma[J]. J Transplant, 2014: 913634.
|
| 76 |
Huang L, Li GM, Zhu JY, et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study[J]. Onco Targets Ther, 2012, 5: 457-462.
|
| 77 |
Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study[J]. Invest New Drugs, 2011, 29(6): 1360-1369.
|
| 78 |
Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy[J]. Exp Clin Transplant, 2010, 8(4): 307-313.
|
| 79 |
Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology, 2007, 45(2): 269-276.
|
| 80 |
Satapathy SK, Das K, Kocak M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246.
|
| 81 |
de′Angelis N, Landi F, Nencioni M, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Prog Transplant, 2016, 26(4): 348-355.
|
| 82 |
Mancuso A, Mazzola A, Cabibbo G, et al. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis[J]. Dig Liver Dis, 2015, 47(4): 324-330.
|
| 83 |
Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation[J]. J Vasc Interv Radiol, 2010, 21(3): 333-338.
|